FDA Awards $2.6 Million Grant for Expanded Study of Soligenix’s Hybryte(TM) for CTCL

0
73

New York, New York–(Newsfile Corp. – September 12, 2022) – PCG Digital — Late-stage biopharmaceutical company Soligenix, Inc. (NASDAQ: SNGX) has announced the award of a $2.6 million grant from the FDA to support a study of expanded HyBryte™ treatment, including at-home usage. The FDA’s support will give patients an opportunity to access Soligenix’s HyBryte™ therapy in an open-label setting. HyBryte is a novel skin directed photodynamic therapy for cutaneous T-cell lymphoma (CTCL), a rare skin disease and cancer.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/136717